ESMO Breast Cancer Congress | Conference

postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer

May 19th 2025

An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.

Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer

May 19th 2025

Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer

May 16th 2025

T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.

EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC

May 16th 2025

EL1SSAR data reinforce the importance of PD-L1 assessment to select patients with TNBC with the best outcomes on atezolizumab.

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer

May 16th 2025

Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

May 16th 2025

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer

May 16th 2025

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer

May 16th 2025

Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.

Iza-Bren Shows Preliminary Efficacy, Safety in Heavily Pretreated HER2–/HER2-low Breast Cancer

May 16th 2025

Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.

Analysis of PADA-1 Trial Highlights Kinetics and Determinants of ESR1 Mutations in HR+/HER2– Metastatic Breast Cancer

May 16th 2025

An analysis from PADA-1 showed the emergence of ESR1 mutations was uneven over time in hormone receptor–positive, HER2-negative metastatic breast cancer.

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

May 15th 2025

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

May 15th 2025

Emiltatug Ledadotin generated initial responses and was tolerable in heavily pretreated patients with advanced/metastatic TNBC.

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

May 15th 2025

Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

May 15th 2025

Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.

T-DXd Improves All Outcomes in Post-Hoc Look of DESTINY-Breast06 in HR+, HER2-Low/-Ultralow Metastatic Breast Cancer

May 15th 2025

Treatment with T-DXd improved outcomes vs chemotherapy in pretreated patients with HR-positive, HER2-low/-ultralow metastatic breast cancer.

Imlunestrant Plus Abemaciclib Provides Consistent Benefit Across Key Subgroups of ER+ Advanced Breast Cancer

May 14th 2025

Subgroup analyses from EMBER-3 continued to demonstrated benefits with imlunestrant plus abemaciclib in ER-positive advanced breast cancer.

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

May 17th 2024

Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer

May 17th 2024

PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

May 17th 2024

Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year invasive disease-free survival rates in patients with early-stage breast cancer.

Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer

May 16th 2024

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.